Search is Powered by Google
Breast Cancer News

Study Determines Breast Specific Gamma Imaging Has Higher Specificity Than MRI In Patients With Equivocal Mammograms

Main Category: Breast Cancer
Also Included In: MRI / PET / Ultrasound;  Women's Health / Gynecology;  Clinical Trials / Drug Trials
Article Date: 03 Oct 2007 - 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:5 stars

5 (4 votes)

Health Professional:5 stars

4.67 (6 votes)

Article Opinions: 0 posts

Recently published study results in The Breast Journal indicate that Breast-Specific Gamma Imaging (BSGI) may be more specific than MRI for evaluating patients with equivocal mammographic findings. The study, compiled by Dr. Rachel Brem and colleagues at The George Washington University Medical Center, compared the use of BSGI and MRI for women with an indeterminate mammogram. Standard procedure requires women with an indeterminate mammogram to have additional clinical work-ups.

According to Dr. Brem, Breast Specific Gamma Imaging (BSGI) -- nuclear medicine imaging of the breast -- is a physiologic approach to breast imaging. BSGI uses a high-resolution gamma camera and Tc-Sestamibi. Previous patient examinations demonstrated high-resolution cameras to be superior to conventional gamma imaging for both detecting breast cancer and screening high-risk patients.

"With the advent of high-resolution gamma cameras, further studies of BSGI versus MRI is warranted as both are physiologically-based adjunct imaging modalities for the diagnosis of breast cancer," said Dr. Brem.

Study Methods & Materials

The retrospective study included twenty-three women with an indeterminate breast finding. In these cases, the interpreting radiologist or referring physician had determined BSGI and MRI examinations were necessary. Subsequently, these patients proceeded to biopsy. If a patient's lesion, for which MRI guided biopsy was recommended, was not seen at the time the patient presented for biopsy, then the patient had a short interval follow-up with MRI.

Patients had BSGI with the Dilon 6800 -- a high-resolution, small-field-of-view gamma camera in craniocaudal and mediolateral oblique projections. MRI was performed with a GE 1.5-T system using a dedicated breast coil. The sensitivity, specificity, positive and negative predictive values were calculated for both BSGI and MRI. Statistical significance was determined by comparing the confidence interval of each parameter for BSGI and MRI. All imaging findings were correlated with pathologic diagnosis.

BSGI versus MRI

In the study, thirty-three indeterminate lesions were evaluated. There were a total of 9 pathologically confirmed cancers in 8 patients. Breast MRI resulted in 18 false positive cases while BSGI demonstrated only 7. There was no statistically significant difference in sensitivity of cancer detection between BSGI and MRI. BSGI demonstrated a greater specificity than MRI, 71 percent and 25 percent, respectively.

The study authors concluded, BSGI has comparable sensitivity and greater specificity than MRI for the detection of breast cancer in patients with equivocal mammograms. The smallest cancer detected by BSGI was 3 mm.

Details about BSGI with the Dilon 6800 Gamma Camera

Breast-Specific Gamma Imaging (BSGI), performed with the Dilon 6800, is a molecular breast imaging technique that can see lesions independent of tissue density and thereby discover very early stage cancers. For difficult-to-diagnose patients, BSGI serves as a complementary diagnostic adjunctive procedure to mammography and ultrasound. With BSGI, the patient receives a radioactive tracing agent that is absorbed by all the cells in the body. Cancerous cells in the breast, due to their increased rate of metabolic activity, absorb a greater amount of the tracing agent than normal, healthy cells and generally appear as "hot spots" on BSGI images.

BSGI is ideal for patients with mammograms that are difficult to interpret. The interpretation challenges include dense breast tissue; suspicious areas on a mammogram; lumps that can be felt but not seen with mammography or ultrasound; implants and breast augmentation; scarring from previous surgeries and for women with notable family history of breast cancer.

About Dilon Technologies

Dilon Technologies' signature product is the Dilon 6800 Gamma Camera. Many leading medical centers in the U.S. now offer BSGI, including Cornell University Medical Center, New York; George Washington University Medical Center, Washington, D.C.; Northwestern Memorial Hospital, Chicago and The Rose, Houston. For more information on Dilon Technologies please visit http://www.dilon.com.

Breast -- Specific Gamma Imaging with 99mTc-Sestamibi and Magnetic Resonance Imaging in the Diagnosis of Breast Cancer: A Comparative Study The Breast Journal, Volume 13, Issue 5, September 2007 (Rachel F. Brem, MD, Ivan Petrovitch, MD, Jocelyn A. Rapelyea, MD, Heather Young, PhD, Christine Teal, MD, Tricia Kelly, MD).

Dilon Technologies
http://www.dilon.com


Personalized Homepage Weekly Newsletters Daily News Alerts
Opioid Induced Constipation ADHD Anxiety Asthma Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles All 'How To...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Swine Flu Image

Swine Flu Updates

- Latest Swine Flu News
- What is Swine Flu?
- Map Of H1N1 Outbreaks
- Swine Flu - Top 20 FAQ
- Daily Email News Alerts
Stick with Medical News Today for the latest news updates on swine flu.


These are the most read articles from this news category for the last 6 months:
Top Article Star
Understanding And Treating Triple-Negative Breast Cancer
07 Jan 2009
Triple-negative breast cancer is a subtype of breast cancer that is clinically negative for expression of estrogen and progesterone receptors (ER/PR) and HER2 protein. It is characterized by its unique molecular profile...


Treating HER2+ Breast Cancer image Treating HER2+ Breast Cancer

There are at least four different kinds of breast cancer and each is treated differently. For HER2+ breast cancer, a chemotherapy drug is typically the best option. Here's an overview of the drugs used to treat breast cancer...

Breast Cancer Treatment: Get Involved image Breast Cancer Treatment: Get Involved

Today, breast cancer patients may be treated by a multidisciplinary team of specialists, consisting of nurses, oncologists, surgeons, social workers, nutritionists and genetic counselors. However, patients, too, have a critical role in their treatment...

View more videos...